Menu
Your Cart

Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 50 preps)

Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 50 preps)
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 50 preps)
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 50 preps)
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 50 preps)
Secured Shopping
Best security features
Apostle MiniEnrich Short Fragments Enrichment Kit (20uL x 50 preps)

Apostle MiniEnrich for Enrichment of Short DNA fragments for NIPT and Oncology Applications

Precise DNA sizing can boost sequencing efficiency, reduce cost, improve data quality, and even allow sequencing of low-input samples, while current pervasive DNA sizing approaches are incap- able of differentiating DNA fragments under 200 bp with high resolution (<20 bp). In non-invasive prenatal testing (NIPT), the size distribution of cell-free fetal DNA in maternal plasma (main peak at 143 bp) is significantly different from that of maternal cell-free DNA (main peak at 166 bp). The current pervasive workflow of NIPT and DNA sizing is unable to take advantage of this 20 bp difference, resulting in sample rejection, test inaccuracy, and restricted clinical utility.

The Apostle MiniEnrich Short Fragments Enrichment Kit is a simple, automatable, high-resolution DNA size enrichment workflow on a magnetic nano-platform to exploit this 20 bp size difference and to enrich fetal DNA fragments from maternal blood. Two types of magnetic nanoparticles are included, with one able to filter high-molecular-weight DNA with high resolution and the other able to recover the remaining DNA fragments under the size threshold of interest with >95% yield. Using this method, the average fetal fraction was increased from 13% to 20% after the enrichment, as measured by plasma DNA sequencing. This approach provides a new tool for high-resolution DNA size enrich- ment under 200 bp, which may improve NIPT accuracy by rescuing rejected non-reportable clinical samples, and enable NIPT earlier in pregnancy. It also has the potential to improve non-invasive screening for fetal monogenic disorders, differentiate tumor-related DNA in liquid biopsy and find more applications in auto- immune disease diagnosis.


As published in:

High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing. Zhang et al. Analyst. July 2020, 145, 5733-5739  (PDF)


Configuration:  20uL x 50 preps

Cat #: A190925-50


Documentation

Protocol: https://www.apostlebio.com/minienrich/MiniEnrich_protocol_20x50_01.pdf


More information

$672.50
A new clinical study, led by scientists from MD Anderson Cancer Center and published in Cancer Cell (journal impact factor = 50.3), shows that tumor and cfDNA methylation can be used to identify SCLC subtypes and might guide precision SCLC therapy. Apostle MiniMax cfDNA kit is one of the critical commercial assays listed in this article. Congratulations to this clinical research team. To date, the Apostle MiniMax technology has been used in 2 articles published in Nature Communications, 2 in Nature Medicine, 1 in Science Translational Medicine, 1 in PNAS, and over 60 scientific articles by over 60 international research and clinical teams in different journals.